Tofimilast

• Description :

  Tofimilast is an inhibitor of Phosphodiesterase 4 (PDE4) with an IC50 of 0.14 μM. Tofimilast exerts its anti-inflammatory effects by inhibiting the activity of PDE4, thereby increasing intracellular levels of cAMP[1].

• CAS Number :

  [185954-27-2]

• UNSPSC :

  12352005

• Target :

  Phosphodiesterase (PDE)

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology; Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/tofimilast.html

• Solubility :

  10 mM in DMSO

• Smiles :

  CCC1=NN(C2=C1CCN3C2=NN=C3C4=CC=CS4)C5CCCC5

• Molecular Formula :

  C18H21N5S

• Molecular Weight :

  339.46

• References & Citations :

  [1]Duplantier AJ, et al. SAR of a series of 5,6-dihydro- (9H) -pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase. J Med Chem. 2007 Jan 25;50 (2) :344-9.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• Isoform :

  PDE4